Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (4): 295-298.DOI: 10.3969/j.issn.1673-8640.2018.04.005

• Orginal Article • Previous Articles     Next Articles

Role of serum CX3CL1 in bone metastatic lung cancer

XU Chen, TANG Xiaofeng   

  1. Department of Blood Transfusion,Changzheng Hospital,the Second Military Medical University,Shanghai 200003,China
  • Received:2017-11-26 Online:2018-04-30 Published:2018-04-26

Abstract:

Objective To investigate the role of serum CX3 chemokine ligand 1(CX3CL1) in bone metastatic lung cancer patients. Methods A total of 40 lung cancer patients with bone metastasis and 40 lung cancer patients without distant metastasis(control group) were enrolled. Serum CX3CL1 expression was determined in 80 lung cancer patients(57 cases of adenocarcinoma and 23 cases of squamous carcinoma) by enzyme-linked immunosorbent assay(ELISA). Combined with clinicopathologic analysis,the difference of serum CX3CL1 expression levels was analyzed retrospectively. Results Serum CX3CL1 expression level in metastasis group [(0.69±0.09) ng/mL] was higher than that in non-metastasis group [(0.62±0.06)ng/mL](P<0.001). Among 57 adenocarcinoma cases,serum CX3CL1 expression level in metastasis group (33 cases)[(0.68±0.09)ng/mL] was higher than that in non-metastasis group(24 cases) [(0.61±0.06)ng/mL](P=0.002). Among 23 squamous carcinoma cases,serum CX3CL1 expression level in metastasis group (7 cases)[(0.74±0.05)ng/mL] was higher than that in non-metastasis group(16 cases)[(0.63±0.07)ng/mL](P<0.05). The difference of serum CX3CL1 expression with different primary lesion sizes,ages and sex had no statistical significance(P>0.05). Conclusions Serum CX3CL1 could be used as an independent marker for predicting bone metastasis in lung cancer patients.

Key words: CX3 chemokine ligand 1, Lung cancer, Adenocarcinoma, Squamous carcinoma, Bone metastasis

CLC Number: